Sensus Healthcare (SRTS) Downgraded to “Neutral” at Alliance Global Partners

Alliance Global Partners cut shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a research note issued to investors on Friday, The Fly reports.

Other equities research analysts have also issued research reports about the stock. Roth Capital reissued a buy rating on shares of Sensus Healthcare in a report on Tuesday, February 19th. TheStreet raised shares of Sensus Healthcare from a d rating to a c rating in a report on Thursday, February 14th. ValuEngine lowered shares of Sensus Healthcare from a buy rating to a hold rating in a report on Wednesday, May 1st. Finally, Northland Securities reissued a sell rating and issued a $5.00 price target on shares of Sensus Healthcare in a report on Friday, February 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of $11.04.

Shares of SRTS stock traded down $1.00 on Friday, hitting $5.38. 280,866 shares of the company’s stock traded hands, compared to its average volume of 30,433. Sensus Healthcare has a one year low of $5.31 and a one year high of $9.23. The firm has a market cap of $105.41 million, a P/E ratio of -38.43 and a beta of -0.53.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.11). Sensus Healthcare had a negative net margin of 11.65% and a negative return on equity of 14.30%. The business had revenue of $5.44 million for the quarter, compared to the consensus estimate of $7.81 million. As a group, equities analysts predict that Sensus Healthcare will post 0.02 earnings per share for the current fiscal year.

In other Sensus Healthcare news, EVP Richard Golin sold 5,943 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $7.56, for a total value of $44,929.08. Following the sale, the executive vice president now owns 925,237 shares of the company’s stock, valued at approximately $6,994,791.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 7,203 shares of company stock worth $54,379. Insiders own 41.10% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in SRTS. Renaissance Technologies LLC boosted its stake in shares of Sensus Healthcare by 75.0% during the 3rd quarter. Renaissance Technologies LLC now owns 48,100 shares of the company’s stock valued at $403,000 after purchasing an additional 20,612 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Sensus Healthcare by 48.2% during the 3rd quarter. Vanguard Group Inc. now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Sensus Healthcare by 48.2% during the 3rd quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Sensus Healthcare by 10.2% during the 4th quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock valued at $192,000 after purchasing an additional 2,418 shares in the last quarter. Finally, Northern Trust Corp bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $86,000. 6.51% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Story: Growth Stocks, What They Are, What They Are Not

The Fly

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.